Abstract: Claudins are tight junction proteins with claudin-6 (CLDN6) expression mostly restricted to embryonic and fetal life. Previously reported gene expression microarray analysis showed an increased level of CLDN6 in atypical teratoid rhabdoid tumors (AT/RT) compared with other central nervous system (CNS) tumors and sarcomas. However, there exist conflicting data on expression of CLDN6 as assessed by immunohistochemistry in CNS tumors. We established membranous staining as a specific and reproducible method for evaluating CLDN6 expression based on fetal and adolescent controls. We then evaluated a large group (257) of pediatric tumors using tissue microarrays, including: 47 malignant rhabdoid tumors (MRTs), (31 AT/RTs and 16 non-CNS MRTs); 67 small, round, blue cell tumors (10 Wilms tumors, 10 embryonal rhabdomyosarcomas, 10 neuroblastomas (NBs), 10 synovial sarcomas (SSs), 9 hepatoblastomas (HBs), 9 alveolar rhabdomyosarcomas, and 9 Ewings sarcomas); and 143 CNS tumors (24 medulloblastomas, 21 pilocytic astrocytomas, 14 astrocytomas grade II/III, 13 gangliogliomas, 12 glioblastomas, 12 ependymal tumors, 11 choroid plexus tumors, 10 meningiomas, 8 dysembryoplastic neuroepithelial tumors, 8 oligodendrogliomas, 4 craniopharyngiomas, 2 germinomas, 2 primitive neuroectodermal tumors (PNET), and 2 central neurocytomas). CLDN6 expression was seen in 12 of 31 (39%) AT/RTs, 7 of 16 (44%) non-CNS MRTs, 5 of 10 (50%) Wilms tumors, 1 of 9 (11%) HBs, 2 of 2 (100%) germinomas, 1 of 2 (50%) CNS PNETs, 1 of 24 (4%) medulloblastomas, and 1 of 10 (10%) meningiomas. Ten of 11 (91%) choroid plexus tumors showed apical staining but no concentric membranous staining. Although CLDN6 is expressed in both AT/RTs and MRTs, it is not a specific biomarker as it is expressed in a variety of other pediatric CNS and soft tissue tumors.
M alignant rhabdoid tumor (MRT) is a highly aggressive childhood neoplasm that occurs in the kidney, liver, and soft tissue; it also occurs in the central nervous system (CNS) where it is referred to as atypical teratoid/rhabdoid tumor (AT/RT). MRT is characterized by a polyphenotypic immunohistochemical (IHC) profile, often expressing mesenchymal, epithelial, and/or neuronal markers within the same tumor. MRT and AT/RT are associated with mutations and/or deletions of the SMARCB1 tumor suppressor gene. 4, 33 The loss of SMARCB1 protein expression in these tumors is associated with loss of IHC staining in the proper context. 16, 18 However, with the recognition of other tumors with altered SMARCB1 protein expression by IHC and rare otherwise typical MRTs with retained SMARCB1 expression, there is a need for additional diagnostic biomarkers. 5 In a recent study of gene expression microarray analysis, Birks et al 5 showed an increased level of claudin-6 (CLDN6) in AT/RTs compared with 100 CNS tumors and 15 sarcomas, suggesting a role for CLDN6 as a positive diagnostic marker for MRT in addition to SMARCB1 loss. Claudins are a family of transmembrane proteins that are essential to the structure and function of tight junctions. As such, they help to regulate paracellular transport and also establish and maintain cell polarity in epithelial and endothelial cells. 2, 14, 22 CLDN6 is one of the earliest molecules expressed in embryonic stem cells committed to epithelial differentiation, and its expression is almost entirely restricted to embryonic and fetal life. 1, 8, 12, 30 As increasing research is conducted on the claudin gene family, more information is being discovered on the role of claudins in the etiology of medical diseases in addition to the aggressiveness and survival of neoplasms. 10, 15, 25 Despite the promising gene expression data, there exist conflicting data on the specificity and sensitivity of CLDN6 IHC for the diagnosis of AT/RT compared with other CNS tumors. 3, 5 Birks et al 5 reported positive staining in 7 of 7 AT/RTs and no staining in 26 of 27 other brain tumor samples including medulloblastomas, supratentorial primitive neuroectodermal tumors (PNET), glioblastomas, and a choroid plexus carcinoma, all of which are in the differential diagnosis of AT/RT in the pediatric population. The only non-AT/RT case to demonstrate staining was a single choroid plexus papilloma. By contrast, Antonelli et al 3 reported CLDN6 positivity in only 17 of 59 (29%) AT/RTs, with additional staining reported in medulloblastomas, gliomas, and choroid plexus papillomas. To address these conflicting results and to better evaluate the potential value of CLDN6 as a diagnostic biomarker, we characterized the expression of CLDN6 in normal human tissue and used a tissue microarray (TMA) approach to evaluate the expression of CLDN6 in a group of AT/RTs and MRTs and in a large number of pediatric CNS tumors and non-CNS small, round, blue cell tumors.
MATERIALS AND METHODS

Cases
This study was conducted under the auspices of the Children's Hospital of Philadelphia Institutional Review Board for the use of human tissues. Cases used for both fetal and postnatal controls, and also pediatric tumors, were selected from the files of the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia. For CLDN6 antibody characterization and control tissues, cases of fetal and adolescent autopsies were used. Normally formed fetuses without structural or genetic abnormalities and with minimal to no maceration or tissue autolysis were included. For the adolescent cases, inclusion criteria were ages 13 years or older with minimal tissue autolysis. Five adolescent cases (13 to 19 y) and 7 fetal cases (17 to 22 wk gestation) were included, all of which met the above-mentioned criteria. Whole sections of liver, lung, kidney, and heart were selected from these cases for evaluation.
Pediatric tumor cases were studied using TMAs. A previously existing TMA comprising 36 AT/RT and 16 non-CNS MRT cases was used. 32 Three additional TMAs were constructed: 1 comprising 72 cases of pediatric small, round, blue cell tumors and 2 comprising 148 non-AT/RT pediatric CNS tumors. Molecular data were reviewed to confirm the pathologic diagnosis when available. The TMAs were constructed following previously described methods. 34 In brief, representative tumor areas were delineated on hematoxylin and eosinstained sections and matched directly to corresponding blocks. A cylindrical portion (0.6 mm) of tumor tissue was transferred to the recipient block at specific positions to form a TMA. Evaluation of the TMA confirmed that the appearance of tumor tissue cores corresponded to the original blocks. Cores with artifact, low cellularity, cautery effect, or viable tumor <90% per core were not analyzed. The specific distribution of cases meeting these criteria is summarized by tumor type in Table 1 . The expected pattern of SMARCB1 expression was confirmed for all TMA cases by IHC staining. 16, 18, 20 
IHC Staining
TMAs were heated in a 601C oven for 5 to 10 minutes. CLDN6 antibody (American Research Products, Belmont, MA) was used to stain formalin-fixed, paraffin-embedded TMA and autopsy slides in an identical manner. Slides were rinsed in 2 changes of xylene for 5 minutes each and then rehydrated in a series of descending concentrations of ethanol. They were treated with 0.3% H 2 O 2 /methanol for 30 minutes and placed in a pressure cooker with 0.01 M citrate buffer of pH 7.6. After cooling, they were rinsed in 0.1 M Tris Buffer and then blocked with 2% fetal bovine serum for 15 minutes. Avidin/Biotin blocking was performed using a commercial blocking kit (Vector Laboratories, Burlingame, CA). Slides were then incubated with CLDN6 antibody at a 1:100 dilution overnight at 41C, rinsed, and then incubated with biotinylated anti-rabbit IgG (Vector Laboratories Burlingame, CA) at a 1:200 dilution for 30 minutes at room temperature. After rinsing, the slides were incubated with the avidin-biotin complex (Vector Laboratories, Burlingame, CA) for 30 minutes at room temperature, rinsed, and then incubated with 3,3 0 -Diaminobenzidine (DAKO, Carpinteria, CA) for 10 minutes at room temperature. Counterstaining was performed for 1 minute in Harris Hematoxylin (Fisher Scientific, Pittsburgh, PA). Slides were then rinsed, dehydrated through a series of ascending concentrations of ethanol and xylene, and coverslipped.
Scoring
Stained slides were scanned on an Aperio OS Slide Scanner (Aperio Technologies, Vista, CA) and scored independently by 2 pathologists. CLDN6 staining in autopsy tissue was characterized for tissue distribution, cellular localization (cytoplasmic, membranous, or both), and staining intensity on a semiquantitative scale (negative, weak, moderate, and strong). On the basis of these data, appropriate scoring criterion for tumor cases was determined as the percentage of tumor with membranous staining (0% to 100%) and intensity. Tumor positivity was then defined as the presence of membranous staining identified at 10x magnification in at least 10% of tumor cells in TMA cores.
RESULTS
CLDN6 in Fetal and Adolescent Autopsy Sections
Examples of CLDN6 IHC are shown in Figures 1A to D. Fetal tissues showed the expected distribution of membranous staining within developing epithelial structures and endothelial cells. Sections of liver showed moderate-to-strong CLDN6 positivity in developing bile ducts within the ductal plate region, whereas bile ducts incorporated into the portal tracts were negative to weak. In the lungs, cells lining the alveolar spaces showed strong membranous staining with mild-to-moderate staining in more proximal bronchial structures. Sections of heart showed mild cytoplasmic staining with no membranous component in cardiomyocytes. In the kidney, the zone of nephrogenesis demonstrated moderate-to-strong membranous staining along a spectrum with the more primitive structures staining more intensely than the better-differentiated tubules. Endothelial cells and lymphatics in all fetal tissue sections showed varying degrees of membranous positivity. In the adolescent cases, mildto-strong cytoplasmic staining was seen in peripheral nerves, macrophages, smooth muscles, cardiac muscles, and skeletal muscles. Focal membranous staining was seen in endothelial cells. On the basis of the control tissue evaluation, membranous staining was regarded as most specific for CLDN6. Any potential aberrant cytoplasmic expression of CLDN6 in tumors could not be differentiated from background staining and as a result was not scored. Results of CLDN6 staining in the non-CNS tumors are shown in Table 2 . All 9 alveolar rhabdomyosarcomas, 10 embryonal rhabdomyosarcomas, 10 SSs, 10 NBs, and 9 Ewing sarcomas were negative for CLDN6 staining. Eight epithelial-type HBs were negative, whereas a single case (11%) showed strong membranous staining in 100% of tumor cells (Figs. 2A, B) . Five of 10 Wilms tumors (50%) showed positivity restricted to the epithelial tumor component, with various degrees of staining intensity both between and within the same tumor (Figs. 2C, D) . In general, the better-differentiated tubules showed less staining compared with the more primitive epithelial elements.
CLDN6 in Tumors
Results of CLDN6 staining in the CNS tumors are shown in Table 3 . (Figs. 2E, F) . One of 2 (50%) CNS PNETs showed membranous staining in 20% of cells. Nine meningiomas, including 2 rhabdoid subtypes, were negative, with a single anaplastic lymphoplasmacyte-rich meningioma showing membranous staining in 15% of cells (Fig. 2G) . Of the 24 medulloblastomas, 1 case (4%) showed strong membranous staining in 60% of cells scattered throughout the tissue core. Although negative by our staining criterion (expression in at least 10% of cells), an additional 3 medulloblastoma cases (12%) showed membranous staining in <5% of tumor cells. None of the choroid plexus tumors showed convincing concentric membranous staining. However, 10 of 11 (91%) cases had a unique pattern of positivity with staining limited to the apical pole of the cell perhaps corresponding to the basal lamina (Fig. 2H) , which, in cross-section, simulated concentric membranous staining. The single case without apical or membranous staining was a choroid plexus carcinoma. In addition, significant cytoplasmic positivity was seen, most commonly in reactive and neoplastic astrocytes and glial processes including Rosenthal fibers and eosinophilic granular bodies. Weakto-strong membranous staining was seen in endothelial cells in a variety of tumor types.
DISCUSSION
The diagnosis of MRT was revolutionized by the discovery of SMARCB1 alterations in these tumors with subsequent loss of protein expression detectable by IHC. 16, 18 However, it is increasingly clear that loss of SMARCB1 is not exclusively limited to rhabdoid tumor; a growing number of tumors have been described that also show loss of expression of SMARCB1 by IHC, including renal medullary carcinoma, epithelioid sarcoma, epithelioid malignant peripheral nerve sheath tumor, myoepithelial carcinoma of soft tissue, pediatric undifferentiated sarcomas, some hepatoblastomas, and some schwannomas in patients with schwannomatosis. 7, 9, 17, 21, 28 Conversely, rare MRTs do not show loss of SMARCB1, implicating a possible second locus in the pathogenesis of these tumors. 6, 11 Examples of AT/RTs without mutation Am J Surg Pathol Volume 36, Number 1, January 2012 Claudin-6 Is a Nonspecific Marker or deletion of SMARCB1 but with abnormalities of other components of the SWI/SNF chromatin remodeling complex have recently been described. 13, 26 In this context, detailed characterization of both normal and neoplastic expression of CLDN6 is important to evaluate its potential utility as a diagnostic biomarker to differentiate MRTs from other brain, soft tissue, and renal tumors encountered in the differential diagnosis.
CLDN6 is one of the earliest molecules expressed in embryonic stem cells committed to epithelial differentiation in both murine and human tissues. 15, 22, 29, 30 However, the expression pattern of CLDN6 immunoperoxidase staining in human tissues has not been fully characterized previously. Our results confirmed that membranous expression is observed in a variety of epithelial and endothelial cells in fetal lung, liver, kidney, and heart, with minimal cytoplasmic staining in other fetal tissue types. The distinct membranous expression pattern in fetal tissues supports the use of this staining as the criterion for positivity with the antibody for CLDN6.
Significant cytoplasmic staining was observed in certain adolescent tissues including peripheral nerves, macrophages, smooth muscles, cardiac muscles, and skeletal muscles, whereas focal membranous staining was seen in endothelial cells. The high degree of presumed nonspecific binding of antibody to intermediate filaments in muscle and macrophage debris in nonfetal tissues could not be resolved despite changes to antibody staining conditions and dilutions. Unexpectedly, some degree of membranous staining was seen in endothelial cells in adolescent tissues. Possible explanations include continued CLDN6 expression outside of fetal life or more likely cross-reactivity of the CLDN6 antibody with other claudin proteins as a result of the high homology between different claudins and the polyclonal nature of the CLDN6 antibody. The main candidate for cross-reactivity would be claudin-5, which is known to be abundantly expressed in endothelial cells and take part in the formation of the blood-brain barrier. 23, 24 This is further supported by the finding of endothelial positivity in a number of brain tumor cases.
Regardless of the explanation, it was apparent that cytoplasmic positivity was not specific for CLDN6 expression, which led us to revise previously used staining interpretation so that only the membranous component of staining was scored for our tumor types. Because of the inherent difficulty in distinguishing weak membranous staining from cytoplasmic background staining, a cutoff of at least 10% of cells showing membranous positivity at 10x magnification was established before evaluation of tumor samples. This method of interpretation was validated by the fact that there was 100% concordance between reviewers in determining whether a case should be classified as positive or negative.
Examination of MRTs showed 39% of AT/RTs and 44% of non-CNS MRTs to be positive. Compared with previously evaluated AT/RTs, these results are intermediate between those of Birks et al 5 (100%) and Antonelli et al 3 (29%). Because of the focal nature of staining in approximately half of the positive MRT cases and the use of a TMA in our study, the number of positive cases could be higher in the evaluation of wholemount sections. The similarity between the percentage of positive cases for AT/RTs and other MRTs suggests that overall CLDN6 expression is similar regardless of CNS or non-CNS location. This is further supported by a recently reported case of a congenital MRT presenting in the axilla that showed CLDN6 positivity. 27 No staining differences were identified between the supratentorial and infratentorial AT/RT. Although the number of cases is limited, both renal rhabdoid tumors in our series were negative, whereas all 3 of those in the liver were positive. We also compared the age at diagnosis of CLDN6-positive and CLDN6-negative MRT cases. Although there was a correlation between positive staining and younger age at diagnosis, it was not statistically significant. Birks et al 5 previously reported a lack of correlation between CLDN6 expression and survival. However, the range of treatments used for patients in this study precluded our ability to correlate survival data with expression of CLDN6.
The majority of small, round, blue cell tumors evaluated were negative, including all rhabdomyosarcomas, NBs, SSs, and Ewings family of tumors. These results are The most robust staining in the small, round, blue cell tumors was observed in a single HB with strong, diffuse membranous staining in both tumor cores, whereas the other 8 HBs and hepatocytes in fetal liver cases were completely negative. All HBs studied were of the epithelial type, including fetal or fetal and embryonal; they were collected between 2004 and 2010 and received similar preresection chemotherapy. The positive case was from a 3-year-old girl with stage III unresectable HB with pure fetal histology and retained SMARCB1 expression on biopsy. Despite receiving chemotherapy including cisplatin, vincristine, and 5-FU, she returned 3 months later with an increase in tumor size and extension of the tumor into the retroperitoneum. Subsequent to resection, the patient was lost to follow-up; however, this was the only patient with tumor growth and extension during the course of chemotherapy.
Most, but not all, of the CNS tumors evaluated showed no expression of CLDN6. Conflicting results for astrocytic tumors have been reported. Birks et al 5 showed no staining in 3 glioblastomas, and KleinschmidtDemasters 19 reported no staining in 10 cases. On the contrary, Antonelli et al 3 reported staining in 1 of 6 lowgrade gliomas and in 7 of 33 high-grade gliomas. The conflicting data may result from differences in interpretation due to cytoplasmic positivity seen in some astrocytes and astrocyte processes in these tumors and due to membranous staining identified in vessels. Of the 10 meningiomas, including 2 rhabdoid meningiomas, only 1 anaplastic lymphoplasmacyte-rich case showed limited CLDN6 positivity.
Among non-MRT embryonal CNS tumors, we observed positive staining in 1 of 24 (4%) of medulloblastomas and extremely focal staining (<5% of cells) in 3 other cases, whereas Birks et al 5 reported no staining in 13 cases, and Antonelli et al 3 showed staining in 6 of 10 (60%) cases. We also observed positive staining in 1 of 2 supratentorial PNETs. Taken together, these data support limited expression in a subset of non-MRT CNS embryonal tumors.
Choroid plexus tumors showed a unique pattern of staining limited to the apical portion of the cell in a linear pattern in 8 papillomas, in 1 atypical papilloma, and in 1 carcinoma. The other choroid plexus carcinoma was completely negative. IHC staining for CLDN6 by Antonelli et al 3 revealed 2 positive papillomas and a negative carcinoma, whereas Birks et al 5 showed positivity in 1 of 7 papillomas and a negative carcinoma. Birks et al 5 also showed an increased level of CLDN6 messenger ribonucleic acid expression in a choroid plexus papilloma but not in a choroid plexus carcinoma. These data suggest that CLDN6 staining in choroid plexus tumors, although in an incompletely membranous pattern, may reflect upregulated CLDN6 protein expression, most commonly seen in lower-grade tumors.
The most striking examples of CNS tumor positivity were seen in the 2 cases of germinomas, which showed strong diffuse membranous positivity in 100% of cells. This was an unexpected result, based on a previous evaluation of CLDN6 in germ cell tumors of the testis that demonstrated no positivity in 13 seminomas but weak-to-moderate membranous positivity in a subset of embryonal carcinomas, teratocarcinomas, teratomas, and choriocarcinomas. 31 The significance of discordant expression of CLDN6 in seminomas and CNS germinomas is uncertain but warrants further evaluation.
In conclusion, on the basis of our characterization of CLDN6 expression in non-neoplastic tissues, we believe that a membranous pattern of expression is most likely of biological significance. Although CLDN6 expression can be identified in both AT/RTs and non-CNS MRTs, it is of limited sensitivity, showing expression in only a subset of these tumors. CLDN6 expression is not specific to AT/RTs and non-CNS MRTs and is observed both in other CNS and non-CNS pediatric tumors. In the CNS, CLDN6 was expressed in choroid plexus tumors and, less frequently, in CNS PNET and meningiomas. Most striking was the unexpected pattern of expression in CNS germinomas, suggesting the need for future studies to further characterize the role of CLDN6 in these tumors. Outside of the CNS, expression of CLDN6 was observed in Wilms tumors and HBs. These results suggest that, although CLDN6 expression may have potential utility when combined with other more sensitive and specific biomarkers of AT/RT and non-CNS MRT, CLDN6 is not reliable as a primary diagnostic biomarker for these tumors.
